首页 › 慢性淋巴细胞白血病 › 得克萨斯州 › Dallas
Dallas TX 慢性淋巴细胞白血病临床试验
10项针对 慢性淋巴细胞白血病的研究正在 Dallas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Baylor University Medical Center, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Baylor Scott & White Health, Dallas
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- UT Southwestern Medical Center, Dallas
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Texas Oncology - Sammons Cancer Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
招募中3 期
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- UT Southwestern Medical Center, Dallas
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH29 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA21 项研究
- Rochester, MN19 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI14 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
Dallas的其他研究
- 乳腺癌54 项研究
- 非小细胞肺癌52 项研究
- 心力衰竭42 项研究
- 转移性癌症42 项研究
- 癌症（所有类型）38 项研究
- 前列腺癌36 项研究
- 结直肠癌33 项研究
- 肥胖症31 项研究
- 卵巢癌28 项研究
- 膀胱癌27 项研究
- 肺癌27 项研究
- 子宫内膜癌25 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。